HYMPAVZI
As Pfizer backs out of hemophilia gene therapy space, CSL hopes Hemgenix is here to stay
Hemgenix, SMPX gene, Pfizer, gene therapy, alternatives, HYMPAVZI, Clinical Trials
Pfizer’s Breakthrough Hemophilia Drug Hympavzi Wins EU Approval
Pfizer, Hympavzi, EU approval, hemophilia A, hemophilia B, marstacimab, once-weekly subcutaneous treatment, pre-filled auto-injector pen
Pfizer’s HYMPAVZI Receives FDA Approval for Hemophilia A and B Treatment
HYMPAVZI, marstacimab-hncq, hemophilia A, hemophilia B, FDA approval, Pfizer, subcutaneous treatment, anti-TFPI inhibitor
Pfizer Secures Second FDA Approval for Hemophilia Treatment in Six Months
Pfizer, FDA approval, Hemophilia, Gene Therapy, Hemophilia B, HYMPAVZI